Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Alector	Replimune Group	C4 Therapeutics	Ocugen	Translate Bio
Symbol	NASDAQ:ALEC	NASDAQ:REPL	NASDAQ:CCCC	NASDAQ:OCGN	NASDAQ:TBIO
Price Information
Current Price	$16.35	$35.84	$34.28	$9.19	$19.43
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.3	1.5	1.4	1.0	1.6
Analysis Score	3.5	3.5	3.5	1.3	4.3
Community Score	2.4	2.4	3.1	3.3	1.8
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	1.7	0.0	0.0	1.7
Earnings & Valuation Score	0.0	0.0	0.6	0.6	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$34.40	$56.00	$44.50	$6.55	$25.70
% Upside from Price Target	110.40% upside	56.25% upside	29.81% upside	-28.69% downside	32.27% upside
Trade Information
Market Cap	$1.30 billion	$1.67 billion	$1.48 billion	$1.73 billion	$1.46 billion
Beta	1.08	2.63	N/A	3.56	0.96
Average Volume	624,227	384,547	275,706	74,082,680	1,177,359
Sales & Book Value
Annual Revenue	$21.22 million	N/A	N/A	N/A	$7.80 million
Price / Sales	61.46	N/A	N/A	N/A	187.40
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$2.83 per share	$5.01 per share	N/A	$0.21 per share	$2.56 per share
Price / Book	5.78	N/A	N/A	N/A	7.59
Profitability
Net Income	$-105,390,000.00	$-52,630,000.00	N/A	$-20,240,000.00	$-113,290,000.00
EPS	($1.71)	($1.54)	N/A	($1.48)	($1.84)
Trailing P/E Ratio	N/A	N/A	0.00	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-757.78%	N/A	N/A	N/A	-70.38%
Return on Equity (ROE)	-53.86%	-30.23%	N/A	-47.72%	-27.54%
Return on Assets (ROA)	-31.44%	-24.66%	N/A	-30.78%	-12.82%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.13%	N/A	0.13%	N/A
Current Ratio	6.61%	19.47%	5.22%	4.78%	5.73%
Quick Ratio	6.61%	19.47%	5.22%	4.78%	5.73%
Ownership Information
Institutional Ownership Percentage	61.50%	55.79%	N/A	8.53%	92.90%
Insider Ownership Percentage	13.90%	50.90%	N/A	3.54%	12.30%
Miscellaneous
Employees	171	122	99	15	122
Shares Outstanding	79.76 million	46.49 million	43.19 million	188.17 million	75.23 million
Next Earnings Date	8/10/2021 (Estimated)	6/2/2021 (Estimated)	6/10/2021 (Estimated)	8/13/2021 (Estimated)	8/5/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable

Source	Headline
	Results: Translate Bio, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates finance.yahoo.com - May 9 at 1:41 PM
	Evercore ISI Stick to Their Hold Rating for Translate Bio Inc investing.com - May 9 at 8:41 AM
	Translate Bio Inc. [TBIO] Stock trading around $18.74 per share: What’s Next? dbtnews.com - May 7 at 10:11 AM
	Translate Bio, Inc. (TBIO) Reports Q1 Loss, Misses Revenue Estimates finance.yahoo.com - May 6 at 11:06 PM
	TBIO Crosses Below Key Moving Average Level nasdaq.com - May 6 at 6:06 PM
	Translate Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update finance.yahoo.com - May 6 at 6:06 PM
	Translate Bio (NASDAQ:TBIO) Trading Down 13.1% americanbankingnews.com - May 6 at 1:54 PM
	Translate Bio, Inc. (NASDAQ:TBIO): How Much Is It Worth And What Should Investors Do? marketingsentinel.com - May 1 at 3:07 PM
	Will Translate Bio, Inc. (TBIO) Report Negative Q1 Earnings? What You Should Know finance.yahoo.com - April 29 at 8:32 PM
	Translate Bio to Present at the 7th Annual Truist Securities Life Sciences Summit finance.yahoo.com - April 28 at 8:27 AM
	Translate Bio (NASDAQ:TBIO) Shares Down 2.5% americanbankingnews.com - April 23 at 11:58 AM
	Translate Bio (NASDAQ:TBIO) Shares Up 7.5% americanbankingnews.com - April 22 at 1:58 PM
	Translate Bio, Inc. (NASDAQ:TBIO) Stock Could Reward Investors With a 41.56% Gain marketingsentinel.com - April 21 at 12:16 PM
	Translate Bio Announces Publication of Preclinical Results of COVID-19 mRNA Vaccine Candidate ... apnews.com - April 20 at 6:12 AM
	Translate Bio Announces Publication of Preclinical Results of COVID-19 mRNA Vaccine Candidate MRT5500 in npj Vaccines sg.finance.yahoo.com - April 19 at 7:39 AM
	First Week of June 18th Options Trading For Translate Bio (TBIO) nasdaq.com - April 16 at 8:12 PM
	Translate Bio (NASDAQ:TBIO) Trading 5% Higher americanbankingnews.com - April 15 at 11:37 AM
	Translate Bio Inc (TBIO) investing.com - April 15 at 6:45 AM
	Wall Street’s Take On Translate Bio, Inc. (NASDAQ:TBIO) Stock stocksregister.com - April 12 at 12:40 PM
	Translate Bio Inc. [TBIO] Stock trading around $17.26 per share: What’s Next? dbtnews.com - April 12 at 7:40 AM
	Translate Bio, Inc. (TBIO) investors to reap big returns again marketingsentinel.com - March 25 at 1:24 PM
	Translate Bio Appoints Dr. Rand Sutherland as President finance.yahoo.com - March 22 at 8:47 AM
	TBIO Stock Price Fell Over 30% Intraday: Why It Happened pulse2.com - March 19 at 9:37 AM
	Why Translate Bio Shares Are Tanking Today finance.yahoo.com - March 18 at 2:24 PM
	Translate (TBIO) Down on Unsatisfactory CF Drug Study Results msn.com - March 18 at 9:24 AM

Date	Company	Brokerage	Action
4/26/2021	Alector	Morgan Stanley	Boost Price Target
1/15/2021	Alector	Bank of America	Initiated Coverage
11/11/2020	Alector	Smith Barney Citigroup	Lower Price Target
7/29/2020	Alector	Barclays	Lower Price Target
6/24/2020	Alector	HC Wainwright	Initiated Coverage
4/28/2020	Alector	The Goldman Sachs Group	Initiated Coverage
3/5/2020	Alector	Citigroup	Initiated Coverage
2/18/2020	Alector	Stifel Nicolaus	Initiated Coverage
12/16/2019	Alector	Cowen	Reiterated Rating
11/27/2019	Alector	BTIG Research	Initiated Coverage
3/4/2019	Alector	SVB Leerink	Initiated Coverage
11/6/2020	Replimune Group	BMO Capital Markets	Boost Price Target
11/2/2020	Replimune Group	Jefferies Financial Group	Initiated Coverage
10/14/2020	Replimune Group	Roth Capital	Boost Price Target
10/14/2020	Replimune Group	Chardan Capital	Boost Price Target
6/3/2020	Replimune Group	Wedbush	Reiterated Rating
10/28/2020	C4 Therapeutics	UBS Group	Initiated Coverage
5/7/2021	Ocugen	Cantor Fitzgerald	Downgrade
3/24/2021	Translate Bio	Truist Securities	Reiterated Rating
3/24/2021	Translate Bio	Evercore ISI	Reiterated Rating
3/19/2021	Translate Bio	William Blair	Reiterated Rating
6/26/2020	Translate Bio	SunTrust Banks	Initiated Coverage

(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources